Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 2/20 | 0.50 |
| ▸ | RARB | P10826 | 2/20 | 0.50 |
| ▸ | RARG | P13631 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889434 | 0.97 | RARA (0.51) | RARARARBRARGSMN1; SMN2PPARG | |
| SCHEMBL202382 | 0.90 | RARA (0.48) | RARARARBRARGSMN1; SMN2PPARG | |
| SCHEMBL6697513 | 0.90 | PPARG (0.44) | RARARARBRARGPPARGPPARA | |
| SCHEMBL820915 | 0.87 | PPARA (0.49) | PPARGPPARAGAAALOX5PDE10A | |
| SCHEMBL4034919 | 0.86 | RARA (0.49) | RARARARBRARGSMN1; SMN2HRH3 | |
| SCHEMBL4889138 | 0.86 | PPARG (0.42) | RARARARBRARGPPARGPPARA | |
| SCHEMBL7922445 | 0.85 | MEN1 (0.45) | PPARGPPARAHRH3ALDH1A1MAPT | |
| SCHEMBL4889260 | 0.85 | RARA (0.41) | RARARARBRARGPPARGPPARA | |
| SCHEMBL19938082 | 0.85 | RARA (0.48) | RARARARBRARGSMN1; SMN2PPARG | |
| SCHEMBL1436666 | 0.84 | PPARG (0.48) | PPARGPPARAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015028960-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS GPR AGONISTS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-03-05 | — | — | WO | disclosed |
| EP-2098517-B1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | MSD KK (JP) | 2013-12-18 | — | — | EP | disclosed |
| US-8367708-B2 | Phenyl-isoxazol-3-ol derivative | MSD K.K. (JP) | 2013-02-05 | — | — | US | disclosed |
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | disclosed |
| EP-1537091-B1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100130559-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| CN-1713907-B | N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | disclosed |
| CN-1816550-B | Indolyl derivatives substituted with a thiazole ring and their use as PPAR modulators | HOFFMANN LA ROCHE | 2010-04-28 | — | — | CN | disclosed |
| EP-2098517-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-09 | — | — | EP | disclosed |
| WO-2002030895-A1 | SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002018355-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | disclosed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | disclosed |
| EP-1102757-A1 | SUBSTITUTED OXAZOLE AND THIAZOLE DERIVATIVES AS HPPAR GAMMA AND HPPAR ALPHA ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2001-05-30 | — | — | EP | disclosed |
| WO-2001021602-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2000008002-A1 | SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2000-02-17 | — | — | WO | disclosed |
| CN-1218460-A | Substituted 4-hydroxy-phenylalcanoic acid derivatives with activity to ppar-'gamma' | GLAXO GROUP LTD (GB) | 1999-06-02 | — | — | CN | disclosed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130559-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | GPR119, FFAR3, FFAR2 | RARA 436/4885RARB 366/4885RARG 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.